ArticleNature chemistry2023
In vivo metallophilic self-assembly of a light-activated anticancer drug.
Article in Nature chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Metallodrugs in the battle against non-small cell lung cancer: unlocking the potential for improved therapeutic outcomes.Frontiers in pharmacology · 2023Pooled it
- A NIR-II AIEgen with superior fluorescence and photothermal performance for precision theranostics.Science advances · 2026Article
- Subcellular photochemistry for precision spatial protein targeting.Nature reviews. Chemistry · 2026Review
- NIR-II photothermal-driven pulsatile PTH release for osteoporotic bone repair.National science review · 2026Article
- A Molecular Trimming Strategy for Hypoxia-Tolerant Photosensitizers With Enhanced cGAS-STING Activation.Angewandte Chemie (International ed. in English) · 2026Article
- Light-Activatable Nitric Oxide Release via Intramolecular Electron Transfer for Tumor Pyroptosis Induction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Hydroxyl-radical-specific cascade photogeneration for oxygen-chain photocatalytic therapy.Chemical science · 2026Article
- Self-Adaptive Charge Transfer States in Aqueous Solutions Promote Fast Intersystem Crossing in a Photosensitizer for Tumor Inhibition.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Novel 2-(2'-Benzothiazolyl)-benzimidazole-Based Iridium(III) Photocatalysts Exhibit Antiproliferative Effects in 2D and 3D Cancer Cells to Bypass Hypoxia-Induced Resistance.Journal of medicinal chemistry · 2026Article
- Article
- The application of metal nanomaterials in cancer diagnosis and treatment.Discover nano · 2026Review
- Proteolysis-targeting chimera (PROTAC) nanomedicines toward cancer treatment: From synthesis to therapeutic delivery.Biomaterials · 2026Review
- ADMET Profiling of the Metallodrugs: A Comparative Review of Platinum, Palladium, Gold, Ruthenium, Copper, and Zinc Anticancer Complexes.Bioinorganic chemistry and applications · 2026Review
- Estrogen-Functionalized Ru(II) Polypyridyl Complexes Self-Assemble into Aggregates and Exhibit Selective Phototoxicity against Breast Cancer Cells.Inorganic chemistry · 2025Article
- Molecular design and excited state dynamics regulation in phototheranostics.Biophysics reports · 2025Article
- Organic-inorganic covalent selenium reversing ischemic reperfusion injury.Nature communications · 2025Article
- Brightening New Horizons: Luminescent Transition Metal Complexes in Optical Imaging and Theranostic Applications.ACS central science · 2025Review
- Ligand supplementation restores the cancer therapy efficacy of the antirheumatic drug auranofin from serum inactivation.Nature communications · 2025Article
- Light-driven secondary structural remodeling in biomimetic nanosystem to enhance tumor chemo-phototherapy.Materials today. Bio · 2025Article
- Rhodium-based metallodrugs for biological applications: current status and future perspectives.Materials today. Bio · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Self-assembling molecular drugs combine the easy preparation typical of small-molecule chemotherapy and the tumour-targeting properties of drug-nanoparticle conjugates. However, they require a supramolecular interaction that survives the complex environment of a living animal. Here we report that the metallophilic interaction between cyclometalated palladium complexes generates supramolecular nanostructures in living mice that have a long circulation time (over 12 h) and efficient tumour accumulation rate (up to 10.2% of the injected dose per gram) in a skin melanoma tumour model. Green light activation leads to efficient tumour destruction due to the type I photodynamic effect generated by the self-assembled palladium complexes, as demonstrated in vitro by an up to 96-fold cytotoxicity increase upon irradiation. This work demonstrates that metallophilic interactions are well suited to generating stable supramolecular nanotherapeutics in vivo with exceptional tumour-targeting properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.